Perinatal Mood Disorders

Postpartum depression affects 14 percent of women and is unique in that it can be a devastating disease to both mother and child. It impairs maternal functioning, is associated with poor nutrition and health in the offspring and can interfere with breastfeeding, maternal-infant bonding and the care of the infant. In addition, postpartum depression is associated with abnormal development, cognitive impairment and psychopathology in children. Postpartum depression affects 14 percent of women. Among patients with postpartum depression, onset occurs before or during pregnancy in approximately 50 percent.

This webinar will provide an overview of the perinatal period and its associated psychiatric conditions, focusing on perinatal mood disorders. The featured speakers will discuss the current landscape of available therapies for perinatal mood disorders, current gaps in treatment, the regulatory landscape and considerations for clinical trials.

Attendees will learn first-hand from members of a multidisciplinary team that successfully support peripartum related clinical trials about the following:

Different conditions that are associated with perinatal period:

• Perinatal insomnia
• Perinatal mood disorders
• Perinatal anxiety
• Postpartum psychosis

Therapies available:

• Psychotropics
• Specialised treatments
• Digital therapeutics

Register to gain insights into perinatal mood disorders, available therapies and clinical trial considerations from a multidisciplinary team in this webinar.

Speakers

Dr. Monica Lee, MD, Medical Director, Medical Affairs, ICON plc

Dr. Monica Lee is a board-certified Obstetrician Gynecologist with over 15 years of clinical experience and is a North American Menopause Society Certified Menopause Practitioner. She graduated from Stanford University with honors and went on to obtain her MD at University of California San Francisco. Subsequently, she finished her residency training in obstetrics and gynecology at University of California Los Angeles. She enjoys teaching and has been involved with Cedars Sinai, UCLA and USC residency training as well as Stanford Bioengineering student mentorship. She subsequently has had experience as a Phase 2-4 clinical trial investigator, consultant for pharmaceutical protocol development on the sponsor side, medical director at a digital health startup and advisor to a Venture Capital firm. She joined ICON as a Medical Director of Women’s Health in 2021 and has contributed to studies as both a medical monitor and as a therapeutic expert.

Message Presenter

Dr. Louisa Steinberg, MD, PhD, Senior Director, Drug Development and Consulting Services, ICON plc

Dr. Louisa Steinberg is a board-certified Psychiatrist with 20 years of CNS research experience. She graduated from the Medical Scientist Training Program at Albert Einstein College of Medicine with a PhD in neuroscience and subsequently went on to do her residency training in psychiatry at Columbia University. After completing a clinical research fellowship focusing on mood disorders at Columbia, Dr. Steinberg became assistant professor in Psychiatry at NYU Grossman School of Medicine and the Nathan Kline Institute for Psychiatric Research. She joined ICON as a Medical Director in the CNS group in 2021 and has contributed to studies as both a medical monitor and as a therapeutic expert. Dr. Steinberg has a long-standing interest in women’s health, particularly how hormonal changes throughout the life cycle affect neurobiology and mental health.

Message Presenter